I think it entirely depends on the strength of the data generated from the trials. If the data is statistically significant, but not overwhelming we will likely be required to do a Ph3 for M2M, and finish the Ph3 for Severe.

However, if the data is incontrovertible, I think we will get an approval of some sort.